Clinical trials: Intraductal Papillary Mucinous Neoplasm
Pancreatic Cancer
Stool Testing for Pancreatic Cancer
The purpose of this study is to determine if pancreatic cancer/pre-cancer can be detected in early stages through the molecular analysis of stool samples.
- Trial name
- NCT01104129
- Where
- United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Columbia University
Surgery Risk Assessment
Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas
The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas.
- Trial name
- NCT06311032
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge with 5-year survival rates of 13%, primarily attributable to advanced-stage diagnosis (AJCC Stage III/IV in >80% of cases).
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraepithelial Neoplasias, Intraductal Papillary Mucinous Neoplasm
- Trial name
- AI-PANC (NCT06638866)
- Testing
- PDAC, Pancreatic precursor lesions
- Where
- 3 sites in China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Intraductal Papillary Mucinous Neoplasm
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.
- Trial name
- NCT05433935
- Testing
- Observation
- Where
- China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
McCune-Albright Syndrome, Fibrous Dysplasia
Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome
The investigators' objective is to understand the pathogenesis of diabetes mellitus in Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) by: 1) establishing the contributions of insulin resistance versus impaired insulin…
- Conditions
- McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus
- Trial name
- NCT03520153
- Testing
- Hyperinsulinemic Euglycemic Clamp and 2H20, Hyperglycemic Clamp, Oral Glucose Tolerance Test
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Yale University
Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages.
- Conditions
- Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, High-grade Pancreatic Intraepithelial Neoplasia, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- AI-LDCT-PC (NCT07117045)
- Testing
- Diagnostic Evaluation for Positive AI Findings
- Where
- 5 sites in China
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
IPMN, Pancreatic, Pancreas Cancer
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia).
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Trial name
- NCT06276764
- Testing
- LINFU®
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Pancreatic Cysts
International Registry for Intraductal Papillary Mucinous Neoplasma
A centralized web-based database will be used to track patients with IPMN lesions of the pancreas to study natural history and risk factors for malignant transformation in this multi-center study.
- Trial name
- NCT00828048
- Where
- United States
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
IPMN, Pancreatic Cancer
Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms
BACKGROUND: Patients with trivial branch duct intraductal papillary mucinous neoplasm (BD IPMN) which remain s stable over 5 years reportedly do not have an increased risk of developing pancreatic cancer (PC) compared to the…
- Trial name
- TRIVIAL (NCT07056972)
- Testing
- Discontinuation of surveillance
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Padova
Pancreatic Cyst, Pancreatic Intraductal Papillary-Mucinous Neoplasm
Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
The purpose of this study is to track outcomes and complications of patients at IUMC referred by physicians for EUS-guided pancreatic cyst ablation.
- Conditions
- Pancreatic Cyst, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Cystadenoma, Mucinous, Papillary Mucinous Cystadenoma, Borderline Malignancy
- Trial name
- NCT01643460
- Testing
- 98% Ethanol & Paclitaxel injection
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Indiana University
Familial Pancreatic Cancer, Pancreatic Adenocarcinoma
DCE MRI in Patients With Pancreatic Cancer
This clinical trial studies an imaging technique known as dynamic contrast enhanced magnetic resonance imaging (DCE MRI) in identifying the presence of pancreatic cancer.
- Conditions
- Familial Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm
- Trial name
- NCT02070705
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute